Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

نویسندگان

  • P Ravn
  • S R Weiss
  • J A Rodriguez-Portales
  • M R McClung
  • R D Wasnich
  • N L Gilchrist
  • P Sambrook
  • I Fogelman
  • D Krupa
  • A J Yates
  • A Daifotis
  • G E Fuleihan
چکیده

We studied the effect on bone mass of alendronate treatment for 5 yr and its withdrawal. Four hundred and forty-seven postmenopausal women with normal bone mass entered a 3-yr randomized trial followed by a 2-yr open label extension. Three hundred and eleven women completed the first 3 yr, and 263 consented to continue and completed the extension. We are reporting data from groups using the dose of alendronate currently approved for osteoporosis prevention (5 mg) or from the group in which alendronate treatment was withdrawn: 52 women received alendronate (5 mg) for 5 yr (group I), 56 received 3 yr of placebo followed by alendronate (5 mg) for 2 yr (group II), and 52 received alendronate (20 mg) for 2 yr followed by 3 yr off therapy (group III). In group I, alendronate (5 mg) increased bone mineral density (BMD) at the spine and trochanter by 2.5-3.2% (P < 0.001 vs. baseline) and stabilized total body and femoral neck BMD (change vs. baseline, P = NS) over 5 yr. By the end of 5 yr, BMD was comparable at the spine, hip, and total body in groups I and III. The 3-yr decrease in BMD after withdrawal of alendronate (20 mg) in group III was 1.8-5.7% (P < 0.01 vs. baseline) and similar to the 3-yr decrease in BMD in group II during the initial 3 yr. In conclusion, alendronate (5 mg) for 5 yr or alendronate (20 mg) for 2 yr followed by 3 yr off therapy prevented postmenopausal bone loss. After withdrawal of alendronate (20 mg), bone loss resumed at the normal early postmenopausal rate.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

اثر تزریق داروی سینوپار بر تراکم استخوانی زنان یائسه مبتلا به استئوپروزیس

Background and purpose: Osteoporosis is the most common metabolic bone disease. The aim of this study was to evaluate the effects of teriparatide on the incidence of fractures and bone density in postmenopausal women with osteoporosis. Materials and methods: A clinical trial was performed in all postmenopausal women aged 45-75 years old with osteoporosis attending a teaching hospital affiliate...

متن کامل

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran

&nbsp;&nbsp;&nbsp; Background: Hip, vertebral and wrist fractures are the most common consequences of osteoporosis. This study aimed at analyzing the cost-effectiveness of teriparatide (CinnoPar&reg;), compared with alendronate and risedronate, in the treatment of women aged 60 and over with postmenopausal osteoporosis in Iran. &nbsp;&nbsp; Methods: A decision tree model with a 2-year time hor...

متن کامل

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

INTRODUCTION Osteoporosis is a progressive skeletal disorder that requires long-term treatment. However, there is little guidance regarding optimal treatment duration and what the treatment discontinuation and retreatment criteria should be. Given that bisphosphonates are the most commonly prescribed class of agent for the treatment of osteoporosis, we reviewed the long-term data relating to th...

متن کامل

میزان تغییر تراکم استخوان در زنان یائسه تحت درمان با آلندرونات در مقایسه با هورمون‌های جنسی: یک پیگیری چهار ساله

Background and Objective: Although there are several methods of treatment of osteoporosis, prospective studies to compare their effect on bone density in Iranian population are rare. This study was designed to compare the effect of alendronate and hormone replacement therapy on bone mineral density of postmenopausal Iranian women living in Zanjan.  Materials and Methods: We treated 115 women...

متن کامل

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women

Background: Bisphosphonates (BPs) are used extensively for managing the osteoporosis. There are some controversies on atypical fractures of femur that associated with increase in cortical thickness (CT) and BPs&rsquo; use. In this study, the effects of alendronate consumption were studied on femoral CT as a predictor for atypical fracture. &nbsp; Methods: Forty nine post-menopausal women age...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The Journal of clinical endocrinology and metabolism

دوره 85 4  شماره 

صفحات  -

تاریخ انتشار 2000